High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1137-1145

  Ebrahem, Quteba ^a   Mahfouz, Reda ^a   Ng, Kwok Peng ^a   Saunthararajah, Yogen ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy resistance; Cytidine analogues; Cytidine deaminase; Decitabine; Sanctuary

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTIDINE DEAMINASE; TETRAHYDROURIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TUMOR; LOW DRUG DOSE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; SURVIVAL TIME; XENOTRANSPLANTATION;

EID: 84872796193     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.597     Document Type: Article

References (38)

1. Camiener GW and Smith CG. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. BiochemPharmacol. 1965; 14(10):1405-1416.
2. Neil GL, Moxley TE, Kuentzel SL, Manak RC and Hanka LJ. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer ChemotherRep. 1975; 59(3):459-465.
3. DeSimone J, Heller P, Molokie RE, Hall L and Zwiers D. Tetrahydrouridine, cytidine analogues, and hemoglobin F. AmJHematol. 1985; 18(3):283-288.
4. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM and Egorin MJ. Modulation of gemcitabine (2',2'-difluoro- 2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ClinCancer Res. 2008; 14(11):3529-3535.
5. Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW and Sowers LC. Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. ChemResToxicol. 2009; 22(6):1194-1204.
6. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J andChan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid CommunMass Spectrom. 2006; 20(7):1117-1126.
7. Neil GL, Moxley TE and Manak RC. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Cancer Res. 1970; 30(8):2166-2172.
8. Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, Burchenal JH and Young CW. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer TreatRep. 1979; 63(8):1245-1249.
9. Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B, Raderer M and Scheithauer W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology. 2001; 60(4):313-315.
10. Guan Z, Wang Y, Maoleekoonpairoj S, Chen Z, Kim WS, Ratanatharathorn V, Reece WH, Kim TW and Lehnert M. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. BrJCancer. 2003; 89(10):1865-1869.
11. Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J and Saunthararajah Y. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 2012; 119(5):1240-1247.
12. Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS and Kohn KW. Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro- 5-azacytidine into DNA of mammalian cells. Cancer Res. 1986; 46(11):5511-5517.
13. Schermelleh L, Haemmer A, Spada F, Rosing N, Meilinger D, Rothbauer U, Cardoso MC and Leonhardt H. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res. 2007; 35(13):4301-4312.
14. Momparler RL and Goodman J. In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res. 1977; 37(6):1636-1639.
15. Jones PA and Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20(1):85-93.
16. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, Tran N, Zhang W, Picardo M and Enghild JJ. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoSONE. 2009; 4(2):e4563.
17. Patel K, Dickson J, Din S, Macleod K, Jodrell D and Ramsahoye B. Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 2010; 38(13):4313-4324.
18. Riccardi R, Chabner B, Glaubiger DL, Wood J and Poplack DG. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-Darabinofuranosylcytosine. Cancer Res. 1982; 42(5):1736-1739.
19. Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J and Deere M. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 11137; 48(5):1337-1342.
20. Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J and Akerman S. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)-a pilot study. Leukemia. 1991; 5(11):991-998.
21. Dover GJ, Charache S, Boyer SH, Vogelsang G and Moyer M. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood. 1985; 66(3):527-532.
22. Ho DH, Bodey GP, Hall SW, Benjamin RS, Brown NS, Freireich EJ and Loo TL. Clinica, pharmacology of tetrahydrouridine. JClinPharmacol. 1978; 18(5-6):259-265.
23. Kreis W, Woodcock TM, Gordon CS and Krakoff IH. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer TreatRep. 1977; 61(7):1347-1353.
24. Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, DeMarco LC, Schuster MW and Budman DR. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer ChemotherPharmacol. 1993; 31(6):481-484.
25. Goldenthal EI, Cookson KM, Geil RG and Wazeter FX. Preclinical toxicologic evaluation of tetrahydrouridine (NSC-112907) in beagle dogs and rhesus monkeys. Cancer ChemotherRep3. 1974; 5(1):15-16.
26. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC and Saunthararajah Y. p53 independent epigeneticdifferentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011; 25(11):1739-1750.
27. Richards DA, Sherwood RA, Ndebele D and Rocks BF. Determination of plasma cytidine deaminase activity by HPLC. BiomedChromatogr. 1987; 2(4):148-151.
28. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM and Issa JP. Mechanisms of resistance to decitabine in themyelodysplastic syndrome. PLoS One. 2011; 6(8):e23372.
29. Matsumoto K, Nagahara T, Okano J and Murawaki Y. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep. 2008; 20(4):863-872.
30. Blagosklonny MV. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget. 2012; 3(6):601-607.
31. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget. 2012; 3(6):596-600.
32. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A and Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012; 39(1):97-108.
33. Cruz FD and Matushansky I. Solid tumor differentiation therapy - is it possible? Oncotarget. 2012; 3(5):559-567. 34. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y and Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012; 131(1):18-29.
34. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y and Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012; 131(1):18-29.
35. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J and Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012; 26(2):244-254.
36. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q, Copelan E, Singh H, Maciejewski JP and Saunthararajah Y. Decitabine maintains hematopoietic precursor selfrenewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther. 2010; 9(6):1536-1543.
37. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y and Hoffman R. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood. 2004; 103(11):4102-4110.
38. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B and Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011; 71(4):1431-1441.